Oncogenic src, raf, and ras Stimulate a Hypertrophic Pattern of Gene Expression and Increase Cell Size in Neonatal Rat Ventricular Myocytes*

Stephen J. FullerDagger , Judith Gillespie-Brown§, and Peter H. Sugden

From the Section of Cardiac Medicine, National Heart and Lung Institute Division, Imperial College School of Medicine, London SW3 6LY, United Kingdom

    ABSTRACT
Top
Abstract
Introduction
Procedures
Results
Discussion
References

In response to hormones and growth factors, cultured neonatal ventricular myocytes increase in profile, exhibit myofibrillogenesis, and re-express genes whose expression is normally restricted to the fetal stage of ventricular development. These include atrial natriuretic factor (ANF), beta -myosin heavy chain (beta -MHC), and skeletal muscle (SkM)-alpha -actin. By using luciferase reporter plasmids, we examined whether oncogenes that activate the extracellular signal-regulated kinase cascade (srcF527, Ha-rasV12, and v-raf) increased expression of "fetal" genes. Transfection of myocytes with srcF527 stimulated expression of ANF, SkM-alpha -actin, and beta -MHC by 62-, 6.7-, and 50-fold, respectively, but did not induce DNA synthesis. Stimulation of ANF expression by srcF527 was greater than by Ha-rasV12, which in turn was greater than by v-raf. General gene expression was also increased but to a lesser extent. The response to srcF527 was inhibited by dominant-negative Ha-rasN17. Myocyte area was increased by srcF527, Ha-rasV12, and v-raf, and although it altered myocyte morphology by causing a pseudopodial appearance, srcF527 did not detectably increase myofibrillogenesis either alone or in combination with Ha-rasV12. A kinase-dead src mutant increased myocyte size to a much lesser extent than srcF527 and also did not inhibit ANF-luciferase expression in response to phenylephrine. We conclude that members of the Src family of tyrosine kinases may be important in mediating the transcriptional changes occurring during cardiac myocyte hypertrophy and that Ras and Raf may be downstream effectors.

    INTRODUCTION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

The cardiac myocyte is a terminally differentiated cell that withdraws from cell division at around birth in mammals. In these cells, adaptive hypertrophic growth in response to an increased requirement for contractile power involves increases in cell size, protein content, and myofibrillar organization (reviewed in Ref. 1). There are also changes in gene transcription that distinguish hypertrophy from maturational growth (eutrophy). In response to hypertrophic stimuli, cultured neonatal rat ventricular myocytes initiate a rapid and transient increase in expression of immediate early genes (c-jun, c-fos, and Egr-1), followed by the re-expression of so-called "fetal" genes including atrial natriuretic factor (ANF),1 beta -myosin heavy chain (beta -MHC), and skeletal muscle (SkM) alpha -actin. More chronic exposure to hypertrophic agonists also elicits an increase in the expression of constitutively expressed contractile protein genes such as ventricular myosin light chain-2 and cardiac muscle alpha -actin. Many of these changes are seen during hypertrophy of the rat heart in vivo, providing a justification for the use of this model system (reviewed in Ref. 1).

A wide variety of agonists induce the hypertrophic phenotype in cultured ventricular myocytes. These include agonists acting through G protein-coupled receptors such as endothelin-1 (2, 3), angiotensin II (4, 5), and alpha 1-adrenergic agonists (4, 6, 7). Other hypertrophic stimuli include passive stretch (8-10), phorbol esters that activate protein kinase C isoforms (11, 12), and growth factors acting through receptor protein tyrosine kinases such as fibroblast growth factors (13) and insulin-like growth factor 1 (14, 15). A feature common to each of these stimuli is their ability to activate the extracellular-regulated kinase (ERK) members of the mitogen-activated protein kinase (MAPK) superfamily (16-22). This has prompted the suggestion that activation of ERKs may be a central component of the intracellular signaling mechanism through which hypertrophic agonists exert their effects (16, 17, 23), although it is still not clear whether ERK activation is obligatory or sufficient (19, 24-26).

Activation of ERK1 (p44 MAPK) and ERK2 (p42 MAPK) is brought about by phosphorylation by MAPK kinases (MEKs, for MAPK (or ERK) kinases) (reviewed in Refs. 27-31). MEKs are themselves activated by phosphorylation by MAPK kinase kinases, the best-characterized being the Raf family (c-Raf-1, A-Raf, and B-Raf in higher organisms) (32-35). For agonists acting through receptor protein tyrosine kinases, the intervening steps between receptor occupancy and activation of the Raf right-arrow MEK right-arrow ERK cascade are relatively well established and involve SH2/SH3-containing adaptor proteins such as Grb2 and Shc, guanine-nucleotide exchange factors such as Sos, and activation through GDP/GTP exchange of the small G proteins of the Ras family (reviewed in Refs. 36-38). Ras·GTP mediates the activation of c-Raf-1 by recruiting it to the plasma membrane (39-42), where other reactions that possibly include the phosphorylation of Tyr-340/Tyr-341 by Src family protein tyrosine kinases lead to its full activation (43, 44). Recent evidence shows that A-Raf is also activated synergistically by oncogenic ras and oncogenic src, whereas oncogenic ras alone is sufficient for maximal activation of B-Raf (44). In terms of the hypertrophic response, there is good evidence for a role for activated Ras. Thus, angiotensin II activates Ras in myocytes (45); injection of oncogenic RasV12 initiates hypertrophic changes in myocytes (46), and PE-induced ANF expression is inhibited by a dominant-negative ras mutant (46).

Recent work has suggested that protein tyrosine kinases of the Src family (Src, Fyn, Lyn, etc.) may participate in the coupling of both receptor protein tyrosine kinases and G protein-coupled receptors to ERK activation (reviewed in Refs. 47-51). Indeed, a role for Fyn has been proposed in angiotensin II-induced hypertrophy of the cardiac myocyte (45). Here we have examined the effect of overexpression of srcF527, an oncogenic variant of the c-src protooncogene, on the transcriptional and morphological characteristics associated with the hypertrophic phenotype in cardiac myocytes. We show that srcF527 expression potently activates genes that are up-regulated in response to hypertrophic stimuli, a response in which it may act in concert with Ras and Raf. Our results suggest that non-receptor protein tyrosine kinases such as c-Src may play a role in some of the altered growth responses of myocytes exposed to hypertrophic stimuli.

    EXPERIMENTAL PROCEDURES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Materials-- Sprague-Dawley rats were bred within the National Heart and Lung Institute. Culture medium and other reagents were from Sigma, Life Technologies, Inc., or Merck. The plasmids encoding constitutively active v-Raf and Ha-RasV12 and dominant-negative (DN) Ha-RasN17 and DNRaf were from Professor C. J. Marshall, and those encoding chicken SrcF527 and kinase-dead mutants of c-Src (srcK-) and SrcF527 (srcF527K-) were from Dr. R. M. Marais (both at the Chester Beatty Laboratories, Institute of Cancer Research, London, UK). In SrcF527 the tyrosine residue at position 527 is mutated to phenylalanine rendering it insensitive to phosphorylation and inactivation by the tyrosine kinase Csk. The ANF-luciferase (ANF-LUX) reporter construct pANF(-638)LDelta 5' (7) and pON249 (52) in which beta -gal is expressed from a constitutive cytomegalovirus promoter were kindly provided by Dr. K. R. Chien (Department of Medicine, University of California, San Diego). The AP-1-LUX construct TRE2PRL(-36) was a gift from Drs. J. H. Brown (Department of Pharmacology, University of California, San Diego) and M. G. Rosenfeld (Howard Hughes Medical Institute, University of California, San Diego). The LUX reporter constructs for beta -MHC (53), SkM-alpha -actin (53-55), and the c-fos serum responsive element (SRE) (56) were gifts from Dr. M. D. Schneider (Molecular Cardiology Unit, Baylor College of Medicine, Houston, TX). The LUX reporter plasmids have been described in detail previously (57). Plasmid pNG1 was constructed by subcloning a BamHI-NotI fragment of pPD46.21 (58) (a gift from Dr. A. Fire, Carnegie Institute, Baltimore, MD) encoding a beta -gal gene containing a nuclear localization signal into the BamHI-NotI sites in pBK-cytomegalovirus (Stratagene). Plasmids were purified by polyethylene glycol precipitation (59).

Transient Transfection of Cultured Neonatal Ventricular Myocytes-- Ventricular myocytes were isolated from the hearts of 1-2-day-old rats by a modification of the method of Iwaki et al. (60) as detailed previously (57). Transfections (by the calcium phosphate method) involved the addition of 5 or 15 µg of LUX reporter plasmid, 2 or 4 µg of pON249, and a total of up to 10 µg of test plasmids to 60-mm cell culture dishes containing 1 million cells. For sarcomeric staining, transfections involved the addition of 6 µg of ANF-LUX reporter plasmid, 1.6 µg of pNG1, and 2 µg each of test plasmids to 100,000 cells per well of a 2-well chamber slide. Phenylephrine (PE), when present, was added to a concentration of 10-100 µM (as stated in individual experiments) approximately 20 h after the transfection. After a further 48 h, myocytes were extracted and assayed for LUX and beta -gal as detailed previously (57). Results are presented as the mean ± S.E. of experiments on at least four separate preparations of myocytes.

Determination of Myocyte Size-- To assess the area of transfected myocytes, cells were washed three times with ice-cold Dulbecco's Ca2+/Mg2+-free phosphate-buffered saline (PBS), fixed with 4% formaldehyde in PBS for 10 min, re-washed three times with PBS, and then stained with 0.2 mg/ml 5-bromo-4-chloro-3-indolyl-beta -D-galactopyranoside, 5 mM K4Fe(CN)6, 5 mM K3Fe(CN)6, 2 mM MgCl2 in PBS. Transfected (blue) cells were randomly selected from all areas of the dishes and imaged using a video hardcopier from which the cell area was determined by planimetry.

Immunocytochemistry-- Myocytes were cultured in Permanox 2-well chamber slides pretreated with gelatin (1%) and laminin (20 µg/ml). After fixing as for cell sizing, cells were permeabilized with 0.3% Triton X-100 in PBS (10 min, room temperature), and nonspecific binding sites were blocked with 10% horse serum in 0.3% Triton X-100 in PBS (10 min, room temperature). Antibodies were diluted in 10% horse serum in 0.3% Triton X-100 in PBS, and myocytes were washed three times in PBS between all stages of the immunofluorescence procedure. Nuclearly localized beta -gal was detected using a mouse polyclonal anti-beta -gal primary antibody (Sigma, 1/200 dilution, 1 h at 37 °C), a biotinylated anti-mouse IgG secondary antibody (Amersham Pharmacia Biotech, 1/200 dilution, 30 min at 37 °C) and streptavidin-7-amino-4-methylcoumarin-3-acetic acid (Boehringer Mannheim, 1/400 dilution, 15 min at 37 °C). beta -MHC was subsequently detected by staining with a mouse monoclonal anti-beta -MHC primary antibody (Novacastra, 1/50 dilution, 1 h at 37 °C) and a Texas Red-conjugated anti-mouse IgG secondary antibody (Amersham Pharmacia Biotech, 1/100 dilution, 30 min at 37 °C). To assess DNA synthesis, myocytes were treated with 0.1 mM bromodeoxyuridine (BrdUrd) for 24 h prior to fixing and permeabilizing as above. All subsequent blocking and antibody incubation steps were carried out in 1% bovine serum albumin in 0.1% Tween 20 in PBS. BrdUrd was detected with a mouse monoclonal anti-BrdUrd antibody (clone BU-33, Sigma, 1/500 dilution), followed by a biotinylated anti-mouse IgG secondary antibody and streptavidin-7-amino-4-methylcoumarin-3-acetic acid as above. beta -Gal was detected with a rabbit polyclonal antibody (Organon Teknika, 1/200 dilution) and a Texas Red-conjugated anti-rabbit IgG secondary antibody (Amersham Pharmacia Biotech, 1/100 dilution).

Expression of Results and Statistical Analysis-- The absolute values of chemiluminescence differs considerably between the various reporter constructs. Thus, in Figs. 1-3, results are expressed as the ratio of reporter gene expression in the presence of srcF527, v-raf, and Ha-rasV12 expression plasmids relative to empty vector controls. This facilitates comparison of the relative potencies of the expression plasmids. Results are presented as means ± S.E. For statistical analysis, absolute values of chemiluminescence were used, and significance was assessed by using an unpaired or paired Student's t test as appropriate with a significant difference taken as being established at p < 0.05.

    RESULTS
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Stimulation of Promoter Activities by srcF527, Ha-rasV12, and v-raf-- The proximal 638 base pairs of the ANF promoter are sufficient to confer tissue specificity and inducible expression on the LUX reporter (7). Transfection with srcF527, a constitutively active oncogenic mutant of c-src, stimulated expression of this construct by 62.3 ± 10.3-fold (Fig. 1, panel A). This was significantly greater (p < 0.01) than the stimulation of ANF-LUX by oncogenic Ha-rasV12 (18.0 ± 2.7-fold). Co-transfection with srcF527 and Ha-rasV12 stimulated ANF-LUX expression by 106.1 ± 21.0-fold which was significantly greater than transfection with Ha-rasV12 alone (p < 0.01) but was not significantly greater than transfection with srcF527 alone (Fig. 1, panel A). When LUX expression was normalized for beta -gal expression (Fig. 1, panel B), the effect of srcF527 (7.2 ± 0.8-fold) was still significantly greater (p < 0.02) than activation by Ha-rasV12 (3.7 ± 0.7-fold). Again, the combined effect of srcF527 and Ha-rasV12 (8.3 ± 1.3-fold) was significantly greater than that of Ha-rasV12 alone (p < 0.025) but was not significantly greater than that of srcF527 alone. Since transfection efficiency using the calcium phosphate method is routinely about 2% and independent of the plasmids transfected (57), the reduction in the magnitude of the responses when normalized to beta -gal is a consequence of a global stimulation of gene expression. This is manifest by the activation of beta -gal expression despite it being driven by the constitutive cytomegalovirus promoter. Thus, the fold induction of beta -gal was 4.7 ± 1.1, 7.7 ± 1.7, and 11.6 ± 3.0 for Ha-rasV12, srcF527, and Ha-rasV12 plus srcF527-transfected cells, respectively. srcF527 is therefore a more potent activator of ANF expression than is Ha-rasV12 and, like oncogenic ras (53), srcF527 also has a powerful effect on gene expression in general. Similar conclusions can be drawn from experiments using a LUX reporter responsive to the activation of the AP-1 transcription factor complex (Fig. 1, panels C and D). This reporter has very low basal activity in cardiac myocytes compared with the ANF-LUX transgene, accounting for the greater variability in stimulation when expressed as fold induction by srcF527 and Ha-rasV12.


View larger version (34K):
[in this window]
[in a new window]
 
Fig. 1.   Stimulation of ANF-LUX and AP-1-regulated gene expression by srcF527 and Ha-rasV12. Neonatal cardiac myocytes were transfected with pANF(-638)LDelta 5' or AP-1-LUX (15 µg/dish), pON249 (4 µg/dish), and 5 µg each of srcF527 (in a pEF vector) and Ha-rasV12 (in a pEXV3 vector) or their backbone vector control as appropriate as described under "Experimental Procedures." After a further 48 h the cells were extracted and assayed for LUX and beta -gal expression. The results are the means ± S.E. from four separate myocyte preparations and are expressed as LUX activities (panels A and C) or LUX/beta -gal activity ratios (panels B and D), relative to transfections with the control vectors pEF and pEXV3. Absolute values of LUX (in counts per 4 s) in controls were 3558 ± 1449 for ANF-LUX (panel A) and 977 ± 547 for AP-1-LUX (panel C). Statistical significance is as follows: a, p < 0.05; b, p < 0.02; c, p < 0.01; d, p < 0.005; and e, p < 0.001 versus control.

The specific activation of the ANF and AP-1 reporter genes by srcF527 and Ha-rasV12 shown here contrasts with the reported (53) lack of a specific effect of rasR12 on other reporter genes (SkM-alpha -actin, cardiac-alpha -actin, and beta -MHC) whose up-regulation is also associated with the hypertrophic phenotype. To determine whether this was a peculiarity of the ANF and AP-1 transgenes, the effects of srcF527 and Ha-rasV12 were extended to include some of these alternative marker genes of hypertrophy (Fig. 2). The SkM-alpha -actin-LUX transgene was up-regulated 7.8-fold by Ha-rasV12 and 6.7-fold by srcF527 (Fig. 2, panel A). However, there was only a slight (1.9-fold) activation of the SkM-alpha -actin-LUX/beta -gal ratio (Fig. 2, panel B) indicating that SkM-alpha -actin transcription was not dramatically activated above the general increase in transcription. By using a c-fos-SRE transgene, a similar conclusion was reached for the effect of Ha-rasV12 (2.3-fold activation), but this transgene was specifically activated by srcF527 (9.0-fold activation, see Fig. 2, panels C and D). In contrast, the beta -MHC transgene was specifically activated by both Ha-rasV12 (6.5-fold) and srcF527 (15.9-fold, see Fig. 2, panels E and F). Of possible relevance to these findings, we found that the sensitivity of the SkM-alpha -actin, c-fos-SRE and beta -MHC transgenes to activation by srcF527 (and by Ha-rasV12) was inversely related to their basal activities. Thus, although the absolute LUX activity (arbitrary light units in thousands) in the presence of srcF527 differed by less than 2-fold (142 ± 33, 201 ± 58, and 115 ± 25 for transfections with SkM-alpha -actin, c-fos-SRE and beta -MHC, respectively), the basal activities were 21.4 ± 1.0, 4.6 ± 0.6, and 2.3 ± 0.3 arbitrary light units in thousands, respectively. For ANF-LUX and AP-1-LUX, the basal activities (in thousands of arbitrary light units) were 3.6 ± 1.4 and 0.9 ± 0.5, respectively, and following srcF527 stimulation were 178 ± 34 and 308 ± 113, respectively.


View larger version (42K):
[in this window]
[in a new window]
 
Fig. 2.   Stimulation of SkM-alpha -actin-, c-fos-SRE-, and beta -MHC promoter activity by v-raf, Ha-rasV12, and srcF527. Neonatal cardiac myocytes were transfected with LUX reporter plasmids for SkM-alpha -actin, c-fos-SRE, and beta -MHC (15 µg/dish), pON249 (4 µg/dish), and 5 µg each of v-raf (in a pEXV3 vector), Ha-rasV12 (in a pEXV3 vector), srcF527 (in a pEF vector), or their backbone vector control as described under "Experimental Procedures." After a further 48 h the cells were extracted and assayed for LUX and beta -gal expression. The results are the means ± S.E. from four separate myocyte preparations and are expressed as LUX activities (panels A, C, and E) or LUX/beta -gal activity ratios (panels B, D, and F), relative to transfections with control vectors. Absolute values of LUX (in counts per 4 s) in controls for v-raf and Ha-rasV12 (pEXV3) were 9437 ± 1193 (panel A), 2023 ± 458 (panel C), and 320 ± 66 (panel E). Absolute values for LUX in controls for srcF527 (pEF) were 21,361 ± 1003 (panel A), 4629 ± 605 (panel C), and 2314 ± 319 (panel E). Statistical significance is as follows: a, p < 0.05; b, p < 0.02; c, p < 0.01; d, p < 0.005; and e, p < 0.001 versus control.

The effect of v-raf on promoter activity is also shown in Fig. 2. Expression of v-raf significantly stimulated promoter activity for all three promoters tested, and the effect of v-raf was similar to but slightly lower than that of Ha-rasV12, in keeping with its role as a downstream effector of Ras (reviewed in Ref. 42). To confirm that the relative order of potency of the three oncogenes (srcF527 > Ha-rasV12 >=  v-raf) was not an artifact of the amount of plasmid transfected, the response of ANF-LUX expression was examined over a range of oncogene concentrations. Results from four separate preparations expressed as fold induction of ANF-LUX/beta -gal in response to 0.3, 1, 3, and 10 µg of plasmid, respectively, were as follows: for srcF527, 8.0 ± 1.1, 8.0 ± 0.4, 10.0 ± 0.9, and 10.4 ± 1.5; for Ha-rasV12, 3.7 ± 1.2, 3.5 ± 1.5, 4.5 ± 1.6, and 3.4 ± 0.9; and for v-raf, 2.0 ± 0.5, 2.0 ± 0.5, 2.7 ± 0.7, and 2.5 ± 0.7. Thus, increasing the amounts of oncogene transfected over the range of 0.3 to 10 µg of DNA had no effect on the extent of ANF-LUX induction. The absolute values of LUX observed for any one of the oncogenes also differed by less than 2-fold over this concentration range. This suggests that the amount of oncogene expressed in each case was sufficient to give a maximum response and that the relative potencies of the oncogenes relates to the efficacy with which they stimulate transcription.

Oncogenic srcF527 Does Not Induce DNA Synthesis in Cardiac Myocytes-- To determine whether the ability of srcF527 to induce strong activation of gene expression (Figs. 1 and 2) might reflect a capacity to re-initiate DNA synthesis, myocytes were transfected with srcF527 and subsequently analyzed for BrdUrd incorporation into nuclei. Myocytes transfected with srcF527 were identified by staining for co-transfected beta -gal and did not show any nuclear staining for BrdUrd (results not shown). Thus, the strong effects of srcF527 on gene expression are transcriptional effects and are not the result of changes in DNA synthesis.

Inhibition of srcF527-stimulated Gene Expression by Dominant-negative ras-- The relative order of potency of srcF527, Ha-rasV12, and v-raf is in accord with observations in other cell types that the transforming activity of Src is dependent upon Ras (61) and that of Ras on c-Raf-1 (62). To investigate whether the increase in cardiac gene expression in response to srcF527 requires functional Ras and/or Raf, the effects of DN Ha-rasN17 and DNraf were determined. In this series of experiments ANF-LUX expression was increased about 4-fold by srcF527, and this was inhibited by co-transfection with Ha-rasN17 (Fig. 3). DNraf had a modest but non-significant inhibitory effect (35.9 ± 8.3%) on srcF527-induced ANF-LUX/beta -gal expression and did not significantly potentiate the inhibition by Ha-rasN17 (Fig. 3). However, the results with the DNraf construct were complicated by its effect on beta -gal expression. Transfection with DNraf inhibited srcF527-induced ANF-LUX expression by 50.2 ± 5.2% but also inhibited beta -gal expression in the presence of srcF527 by 36.7 ± 5.6% in these same transfections. Similarly, the DNraf construct reduced beta -gal expression in the presence of Ha-rasV12 and in the presence of 0.1 mM PE by 20.2 ± 2.5 and 71.0 ± 1.3%, respectively (n = 4 separate preparations). Thus, the DNraf construct has a predominantly general effect to depress gene expression and which masks the effects of DNraf on PE-, Ha-rasV12-, and srcF527-induced ANF-LUX expression. These results suggest that transmission of the signal from srcF527 to ANF-LUX expression is mediated through Ras but that Raf may not be the only downstream Ras effector through which the signal is propagated.


View larger version (35K):
[in this window]
[in a new window]
 
Fig. 3.   Inhibition of srcF527-stimulated ANF promoter activity by dominant-negative Ha-rasN17 and DNRaf. Neonatal cardiac myocytes were transfected with pANF(-638)LDelta 5' (5 µg/dish), pON249 (2 µg/dish), and 3 µg each of srcF527 (in a pEF vector), N17Ras (in pEXV3), and DNRaf (in pMT-SM), or their backbone vector control as described under "Experimental Procedures." After a further 48 h the cells were extracted and assayed for LUX and beta -gal expression. The results are the means ± S.E. from four separate myocyte preparations and are expressed as LUX/beta -gal activity relative to controls (CON). Statistical significance is as follows: a, p < 0.02 versus control; b, p < 0.05; c, p < 0.01 versus srcF527.

The Effect of Genistein on ANF-LUX Expression-- It has previously been reported that activation of Ras and induction of ANF expression in cardiac myocytes by PE can be blocked by the tyrosine kinase inhibitor genistein (63). Surprisingly, we found that genistein (20 µM) enhanced ANF-LUX/beta -gal expression in response to srcF527 (Fig. 4, panel A). However, genistein also increased basal ANF-LUX activity to a similar extent in these experiments such that fold induction of ANF-LUX/beta -gal by srcF527 was unaltered by genistein when expressed relative to the genistein control (Fig. 4, panel B). In the light of these unexpected results, we re-examined the effects of genistein on PE- and TPA-induced ANF-LUX expression. Genistein had no effect on the fold activation of ANF-LUX/beta -gal by PE or TPA when expressed relative to the Me2SO control (Fig. 4, panel A). Again, because of its effect on basal ANF-LUX/beta -gal expression, when the results were expressed relative to the matched control, genistein appeared to inhibit PE- and TPA-induced ANF-LUX/beta -gal expression (Fig. 4, panel B). Thus, interpretation of these results is dependent upon the manner in which they are expressed. A possible explanation for the altered responses to TPA and PE in the presence of genistein is that under basal conditions c-Src is kept in an inactive conformation through phosphorylation of tyrosine 527 (in chicken c-Src) in the C-terminal tail by Csk (47, 64). If the tyrosine kinase activity of Csk is more sensitive to inhibition by genistein than is c-Src itself, the net effect of genistein could result in an increase in c-Src activity.


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 4.   Effect of genistein on PE, TPA, and srcF527-stimulated ANF promoter activity. Neonatal cardiac myocytes were transfected with pANF(-638)LDelta 5' (5 µg/dish) and pON249 (2 µg/dish), as described under "Experimental Procedures," except that genistein (20 µM, diluted from a 20 mM stock in Me2SO; solid bars) or 0.1% (v/v) Me2SO (open bars) was included at all stages from 4 h prior to transfection onward. After overnight transfection the cells were incubated for a further 48 h in the presence or absence of 100 µM PE or 1 µM TPA before extraction and assay for LUX and beta -gal expression. In experiments with src 3 µg of srcF527 or pEF backbone vector were included in the transfection mixture. The results are the means ± S.E. from four separate myocyte preparations and are expressed as LUX/beta -gal activity relative to the Me2SO control (panel A) or relative to Me2SO or genistein controls as appropriate (panel B). Statistical significance is as follows: a, p < 0.05; b, p < 0.02 for the effect of genistein versus Me2SO in the presence of the same stimulus.

The Effect of srcF527, Ha-rasV12, and v-raf on Myocyte Size-- As well as characteristic alterations in transcription, hypertrophied cardiomyocytes are larger and more regular in shape than control cells (2, 6, 7, 25, 60, 65). In separate experiments, transfection of myocytes with srcF527, Ha-rasV12, or v-raf significantly increased the size of transfected cells by 68, 129, and 62%, respectively, but there was no additional stimulation in the presence of both Ha-rasV12 and srcF527 (Fig. 5). The increases in cell size induced by these oncogenes were as great as that elicited by maximally effective concentrations of PE (57). To determine whether the increase in cell size by srcF527 is dependent on its kinase activity, the effect of a kinase dead srcF527 mutant (srcF527K-) on myocyte size was determined (Fig. 5, Expt. 3). Whereas srcF527 increased myocyte area by 74.8% (p < 0.001), srcF527K- only increased myocyte area by 22.5% (p < 0.001 versus srcF527), although this was still significantly greater than the controls (p < 0.02). It is unlikely that this is due to any residual kinase activity as srcF527K- was completely ineffective in stimulating ANF-LUX activity (0.8 ± 0.13-fold of control compared with 11.8 ± 0.48-fold of control for srcF527, n = 4). Thus, the ability of srcF527 to induce an increase in cell size is largely dependent on its kinase activity, although there is a small kinase-independent component that may reflect an ability of srcF527 (and srcF527K-) to induce cell spreading.


View larger version (33K):
[in this window]
[in a new window]
 
Fig. 5.   Effects of srcF527, v-raf, and Ha-rasV12 expression on myocyte size. In experiments 1 and 2, neonatal cardiac myocytes were transfected with ANF-LUX (15 µg/dish), pON249 (4 µg/dish), and 5 µg of v-raf, Ha-rasV12, srcF527, or their backbone vector control as described under "Experimental Procedures." In experiment 3 ANF-LUX was omitted, and pON249 and srcF527 (or pEF or srcF527K-) were used at 3 µg/dish each. After a further 48 h the cells were fixed and stained with 5-bromo-4-chloro-3-indolyl-beta -D-galactopyranoside, and cell area was measured by planimetry. Results are means ± S.E. from 40 to 59 randomly chosen transfected cells. Statistical significance is as follows: a, p < 0.001; b, p < 0.02 versus control; c, p < 0.001 for the effect of srcF527K- (SrcK-) versus srcF527.

The Effect of srcF527 on Sarcomeric Organization-- Another feature characteristic of myocytes exposed to hypertrophic agonists is increased assembly and organization of contractile proteins into sarcomeric units (2, 25, 60). To examine the effects of srcF527 on sarcomerogenesis, myocytes were co-transfected with pNG1, a vector that targets beta -gal to the nucleus. This helps to prevent problems with cross-reactivity which can arise when staining proteins in the same intracellular compartment with two primary mouse antibodies. Myocytes were subsequently stained for beta -gal to identify transfected cells (results not shown) and with beta -MHC to highlight the contractile apparatus (Fig. 6). Transfection with empty vector had no effect on sarcomeric organization (Fig. 6, panel A; compare the transfected cell (see arrow) to the surrounding non-transfected cells). Likewise, cells transfected with srcF527 did not display increased organization of the contractile apparatus into sarcomeric structures (Fig. 6, panel B), even though the transfected cell is morphologically distinct with a more clearly defined outline and outgrowth of extended processes/pseudopodia. These probably represent points of contact with the substratum. A combination of srcF527 and Ha-rasV12 enhanced this definition of shape (Fig. 6, panel C), but despite the clear change in size and appearance, there was little evidence of increased sarcomerogenesis when compared with the organization of the myofibrils seen in response to PE (Fig. 6, panel D). Myocytes treated with PE also displayed more defined points of anchorage to the dish.


View larger version (142K):
[in this window]
[in a new window]
 
Fig. 6.   Effects of srcF527 and Ha-rasV12 on myocyte morphology and myofibrillar organization. Myocytes were transfected with pANF(-638)LDelta 5' (6 µg/well), pNG1 (1.6 µg/well), and 2 µg each of srcF527 and Ha-rasV12 or their backbone vector control. After a further 48 h the cells were fixed and stained for beta -MHC by indirect immunofluorescence as described under "Experimental Procedures." Micrographs are shown for the vector control (panel A), srcF527 (panel B), srcF527 plus Ha-rasV12 (panel C), and cells treated with 100 µM PE (panel D). Transfected myocytes (indicated by arrows) were localized by immunofluorescent staining for beta -gal (not shown). The scale bar represents 50 µm.

PE-induced ANF-LUX Is Not Inhibited by Kinase-dead src-- In an attempt to determine whether c-Src may be a component of the intracellular signaling pathway through which PE exerts its hypertrophic transcriptional responses, myocytes were transfected with kinase-dead wild type c-src (srcK-) or srcF527K-, and its effect on PE-induced ANF-LUX was determined. Transfection with srcK- did not affect ANF-LUX/beta -gal expression in response to 10-100 µM PE (fold induction by PE in the absence and presence of 3-20 µg of srcK- was 14.9 ± 3.5 and 20.5 ± 7.1, respectively, n = 7). Similar results were obtained using the srcF527K- construct; fold induction of ANF-LUX/beta -gal by 10 µM PE was 11.6 ± 3.3 and 18.8 ± 4.9 in the absence and presence of 3 µg of srcF527K-, respectively (n = 4). In these experiments beta -gal expression in the presence of srcF527K- was reduced to 50.5 ± 11.2% which accounted for the apparent stimulation of ANF-LUX/beta -gal expression. These results suggest that c-Src may not be an essential component of the pathway through which PE transduces its transcriptional responses. However, these conclusions remain to be substantiated because the efficacy with which these kinase-dead Src mutants can act to inhibit the function of endogenous c-Src is not known.2

    DISCUSSION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

The Src family of non-receptor protein tyrosine kinases is activated by a wide variety of agents (growth factors, cytokines, G-protein-coupled receptor agonists, UV light, etc.) and is intimately connected with cell growth (reviewed in Refs. 47-51 and 66). This is reflected by the ability of oncogenic src to transform cells (61), for which there is a functional dependence on Ras (61). Similarly, the transforming ability of oncogenic ras is dependent on c-Raf-1 (62), and unregulated c-Raf-1 protein kinase activity is itself oncogenic (67). The function of all three protooncogenes is closely interconnected because, although Src and Ras can independently activate c-Raf-1, both are required for full c-Raf-1 activation (43, 44, 68). The same is true for activation of A-Raf but not B-Raf which can be fully activated by oncogenic Ras alone (44). One view is that Ras is required to recruit c-Raf-1 to the plasma membrane where it can be activated by phosphorylation on tyrosine residues 340 and 341 by membrane-bound Src (42-44, 69). B-Raf lacks the tyrosine residues in c-Raf-1 and A-Raf which are phosphorylated by Src, which may explain its lack of sensitivity to activation by Src (44). However, since the activation of c-Raf-1 autokinase activity by v-src is not inhibited by expression of dominant-negative Ha-rasN17, v-src may at least partially activate c-Raf-1 via a Ras-independent pathway (68).

The importance of Ras activation in the hypertrophic response has been demonstrated by the ability of oncogenic Ha-RasV12 protein to induce the characteristic morphological and transcriptional changes in myocytes and for dominant-negative Ha-rasA15 to inhibit the hypertrophic response to PE (46). Oncogenic raf has also been shown to induce the characteristic transcriptional changes in myocytes, although not morphological changes associated with hypertrophy (70). Here we have compared the effects of srcF527, Ha-rasV12, and v-raf with respect to their ability to initiate a gene program associated with hypertrophy (Figs. 1 and 2). The order of potency observed (srcF527 > Ha-rasV12 > v-raf) is in accord with their functional hierarchy as described above and which is reinforced by the observation that Ha-rasN17 inhibits activation of ANF-LUX expression by srcF527 (Fig. 3). DNraf had a lesser specific effect on the response of ANF-LUX to srcF527, suggesting that c-Raf-1 may not be the only downstream effector that can transduce the effects of activated Ras. Other possible Ras effectors include MEK kinase-1, phosphatidylinositol-3-kinase, p120GAP, Ral-GDS and protein kinase Czeta (reviewed in Ref. 71). Of these other potential candidates, MEK kinase-1 and protein kinase Czeta have been shown to induce ANF-LUX when constitutively active forms are overexpressed in cardiac myocytes (72-74), and Ras-GAP (a GTPase-activating protein for Ras) has also recently been proposed to have an effector-like function in these cells (75). Observations in fibroblasts that oncogenic src associates with and phosphorylates Ras-GAP suggests an additional level of complexity to the functional interaction of Src with Ras (76).

As well as these specific transcriptional effects associated with a hypertrophic response, srcF527 and Ha-rasV12 also stimulated general or global gene expression, as previously reported for rasR12 (53). In partial agreement with that study (53), we only detected a 1.6-fold induction of SkM-alpha -actin by Ha-rasV12 when corrected for beta -gal expression (Fig. 2, panel B), although we observed a 6.5-fold activation of beta -MHC under these conditions (Fig. 2, panel F). This discrepancy may be due in part to the different oncogenic ras constructs used or to differences in culture conditions because the stimulation of SkM-alpha -actin-LUX and beta -MHC-LUX reported here was much greater than the effect reported for the Arg-12 Ras construct using the same LUX reporters (53). The ability of both oncogenic src and ras to stimulate general gene transcription after serum withdrawal probably reflects their ability to substitute for growth factors, the responses to which are dependent on the activation of the cellular counterparts of these oncogenes.

The most striking features of myocyte morphology evoked by powerful hypertrophic agonists such as endothelin-1 and PE are an increase in cell size and the organization of the contractile apparatus into sarcomeric structures (Fig. 6, panel D, and Refs. 2, 25, 60). In common with oncogenic ras or raf, srcF527 increased myocyte size, but the effects of Ha-rasV12 and srcF527 were not additive (Fig. 5). This may reflect a limit on the size that these cells can attain under the conditions in which they are cultured. Despite its potent effects on gene transcription and cell size, srcF527, either alone or in combination with Ha-rasV12, did not detectably induce sarcomeric organization (Fig. 6, panels B and C). This result differs from the reported similarity in the pattern of ventricular myosin light chain-2 organization in myocytes microinjected with Ras oncoprotein and myocytes treated with PE (46). However, this could be due to a difference between injection of the Ras oncoprotein and transfection with a Ha-rasV12 expression plasmid because we have consistently failed to observe effects of transfected Ha-rasV12 on sarcomeric structural organization.3

One clear morphological effect of transfection of myocytes with srcF527 or with srcF527 plus Ha-rasV12 is the increased definition of the cell periphery and in particular the contact points with the substratum. A possible explanation for this phenomenon is that c-Src is known to associate with the plasma membrane and especially with focal adhesions (77). Here, it may phosphorylate cytoskeletal proteins, several of which have been described as Src substrates including the focal adhesion kinase p125FAK (78, 79), paxillin (80), and p130Cas (81). In accord with this view, the effects of srcF527 on myocyte morphology were greatly reduced in the absence of Src kinase activity. Indeed, interaction and phosphorylation of Src and p125FAK have been proposed as critical early steps in the process by which cell adhesion initiates intracellular signaling (reviewed in Ref. 49). Another recent report suggests that Src family tyrosine kinases are essential for ERK activation in myocytes in response to hydrogen peroxide (82). It is likely that Src family tyrosine kinases will also serve to transduce the effects of other stimuli in cardiac myocytes, although our initial studies do not support a role for Src in the response to PE.

The lack of effect of srcK- on PE-induced transcription might be interpreted in one of several ways. First, and most obviously, c-Src may not be involved in the hypertrophic response to PE. Second, the hypertrophic response to PE could require c-Src but not its kinase activity, such that transfected srcK- may be equally as effective as c-Src in transducing the effect of PE. However, overexpression of SrcK- or SrcF527K- did not stimulate ANF-LUX expression making this explanation unlikely (results not shown). Third, although PE may signal through c-Src, when this pathway is inhibited by SrcK- other Src family members may be able to substitute for it. Alternatively, the response to PE may require another member of the Src family that is not inhibited by SrcK- but whose effects on activation by PE can be reproduced by srcF527. Another point for consideration is that it is also possible that srcF527 does not stimulate the same pathways as activated endogenous c-Src. Finally, SrcK- and SrcF527K- may not be effective competitors of c-Src. Thus, whether c-Src or one of its family members is involved in the hypertrophic response to PE remains equivocal.

In summary, srcF527 initiates changes in transcription associated with the hypertrophic response, an effect for which it is dependent on Ras. Transfection with srcF527 also increases myocyte size, although it does not increase the organization of the contractile apparatus into sarcomeric units. We conclude that members of the Src family of non-receptor protein tyrosine kinases may be important in mediating the transcriptional responses that occur during the development of cardiac hypertrophy, although the hypertrophic stimuli which may utilize Src as part of their signaling pathway have yet to be defined.

    ACKNOWLEDGEMENTS

We thank Chris Marshall, Richard Marais, Ken Chien, Michael Schneider, Joan Brown, Mike Rosenfeld, and Andy Fire for providing plasmids; and Nicola Haward and Richard Taylor for preparation of the myocytes.

    FOOTNOTES

* This work was supported by a grant from the Biotechnology and Biological Sciences Research Council (to P. H. S. and S. J. F.) and Grant BS1 from the British Heart Foundation (to S. J. F.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger British Heart Foundation Lecturer in Basic Science. To whom correspondence should be addressed: Cardiac Medicine, NHLI Division, Imperial College School of Medicine, Dovehouse St., London SW3 6LY, United Kingdom. Tel.: 44 171-352-8121 (ext. 3309/3314); Fax: 44 171-823-3392; E-mail: stephen.fuller{at}ic.ac.uk.

§ Current address: Beatson Institute for Cancer Research, Garscube Estate, Switchback Road, Bearsden, Glasgow G61 1BD, United Kingdom.

1 The abbreviations used are: ANF, atrial natriuretic factor; beta -gal, beta -galactosidase; beta -MHC, beta -myosin heavy chain; BrdUrd, bromodeoxyuridine; DN, dominant-negative; ERK, extracellular signal-regulated kinase; LUX, luciferase; MAPK, mitogen-activated protein kinase; MEK, MAPK (or ERK) kinase; PBS, Dulbecco's Ca2+/Mg2+-free phosphate-buffered saline; SkM-alpha -actin, skeletal muscle alpha -actin; SRE, serum responsive element; TPA, 12-O-tetradecanoylphorbol-13-acetate; PE, phenylephrine.

2 Richard Marais, personal communication.

3 S. J. Fuller, J. Gillespie-Brown, and P. H. Sugden, unpublished observations.

    REFERENCES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

  1. Chien, K. R., Knowlton, K. U., Zhu, H., and Chien, S. (1991) FASEB J. 5, 3037-3046[Abstract/Free Full Text]
  2. Shubeita, H. E., McDonough, P. M., Harris, A. N., Knowlton, K. U., Glembotski, C. C., Brown, J. H., and Chien, K. R. (1990) J. Biol. Chem. 265, 20555-20562[Abstract/Free Full Text]
  3. Ito, H., Hirata, Y., Hiroe, M., Tsujino, M., Adachi, S., Takamoto, T., Nitta, M., Taniguchi, K., and Marumo, F. (1991) Circ. Res. 69, 209-215[Abstract]
  4. Dostal, D. E., and Baker, K. M. (1992) Am. J. Hypertens. 5, 276-280[Medline] [Order article via Infotrieve]
  5. Sadoshima, J., and Izumo, S. (1993) Circ. Res. 73, 413-423[Abstract]
  6. Lee, H. R., Henderson, S. A., Reynolds, R., Dunnmon, P., Yuan, D., and Chien, K. R. (1988) J. Biol. Chem. 263, 7352-7358[Abstract/Free Full Text]
  7. Knowlton, K. U., Baracchini, E., Ross, R. S., Harris, A. N., Henderson, S. A., Evans, S. M., Glembotski, C. C., and Chien, K. R. (1991) J. Biol. Chem. 266, 7759-7768[Abstract/Free Full Text]
  8. Komuro, I., Kaida, T., Shibazaki, Y., Kurabayashi, M., Katoh, Y., Hoh, E., Takaku, F., and Yazaki, Y. (1990) J. Biol. Chem. 265, 3595-3598[Abstract/Free Full Text]
  9. Komuro, I., Katoh, Y., Kaida, T., Shibazaki, Y., Kurabayashi, M., Hoh, E., Takaku, F., and Yazaki, Y. (1991) J. Biol. Chem. 266, 1265-1268[Abstract/Free Full Text]
  10. Sadoshima, J., Jahn, L., Takahashi, T., Kulik, T. J., and Izumo, S. (1992) J. Biol. Chem. 267, 10551-10560[Abstract/Free Full Text]
  11. Henrich, C. J., and Simpson, P. C. (1988) J. Mol. Cell. Cardiol. 20, 1081-1085[Medline] [Order article via Infotrieve]
  12. Dunnmon, P. M., Iwaki, K., Henderson, S. A., Sen, A., and Chien, K. R. (1990) J. Mol. Cell. Cardiol. 22, 901-910[Medline] [Order article via Infotrieve]
  13. Parker, T. G., Packer, S. E., and Schneider, M. D. (1990) J. Clin. Invest. 85, 507-514[Medline] [Order article via Infotrieve]
  14. Ito, H., Hiroe, M., Hirata, Y., Motoyoshi, T., Adachi, S., Masayoshi, S., Koike, A., Nogami, A., and Marumo, F. (1993) Circulation 87, 1715-1721[Abstract]
  15. Duerr, R. L., Huang, S., Miraliakbar, H. R., Clark, R., Chien, K. R., and Ross, J., Jr. (1995) J. Clin. Invest. 95, 619-627[Medline] [Order article via Infotrieve]
  16. Bogoyevitch, M. A., Glennon, P. E., and Sugden, P. H. (1993) FEBS Lett. 317, 271-275[CrossRef][Medline] [Order article via Infotrieve]
  17. Bogoyevitch, M. A., Glennon, P. E., Andersson, M. B., Clerk, A., Lazou, A., Marshall, C. J., Parker, P. J., and Sugden, P. H. (1994) J. Biol. Chem. 269, 1110-1119[Abstract/Free Full Text]
  18. Yamazaki, T., Tobe, K., Hoh, E., Maemura, K., Kaida, T., Komuro, I., Tamemoto, H., Kadowaki, T., Nagai, R., and Yazaki, Y. (1993) J. Biol. Chem. 268, 12069-12076[Abstract/Free Full Text]
  19. Thorburn, J., Frost, J. A., and Thorburn, A. (1994) J. Cell Biol. 126, 1565-1572[Abstract]
  20. Sadoshima, J., Qiu, Z., Morgan, J. P., and Izumo, S. (1995) Circ. Res. 76, 1-15[Abstract/Free Full Text]
  21. Bogoyevitch, M. A., Andersson, M. B., Gillespie-Brown, J., Clerk, A., Glennon, P. E., Fuller, S. J., and Sugden, P. H. (1996) Biochem. J. 314, 115-121[Medline] [Order article via Infotrieve]
  22. Foncea, R., Andersson, M., Ketterman, A., Blakesley, V., Sapag-Hagar, M., Sugden, P. H., LeRoith, D., and Lavandero, S. (1997) J. Biol. Chem. 272, 19115-19124[Abstract/Free Full Text]
  23. Lazou, A., Bogoyevitch, M. A., Clerk, A., Fuller, S. J., Marshall, C. J., and Sugden, P. H. (1994) Circ. Res. 75, 932-941[Abstract]
  24. Thorburn, J., Carlson, M., Mansour, S. J., Chien, K. R., Ahn, N., and Thorburn, A. (1995) Mol. Biol. Cell 6, 1479-1490[Abstract]
  25. Clerk, A., Gillespie-Brown, J., Fuller, S. J., and Sugden, P. H. (1996) Biochem. J. 317, 109-118[Medline] [Order article via Infotrieve]
  26. Post, G. R., Goldstein, D., Thuerauf, D. J., Glembotski, C. C., and Brown, J. H. (1996) J. Biol. Chem. 271, 8452-8457[Abstract/Free Full Text]
  27. Cobb, M. H., and Goldsmith, E. J. (1995) J. Biol. Chem. 270, 14843-14846[Free Full Text]
  28. Marshall, C. J. (1995) Cell 80, 179-185[Medline] [Order article via Infotrieve]
  29. Malarkey, K., Belham, C. M., Paul, A., Graham, A., McLees, A., Scott, P. H., and Plevin, R. (1995) Biochem. J. 309, 361-375[Medline] [Order article via Infotrieve]
  30. Seger, R., and Krebs, E. G. (1995) FASEB J. 9, 726-735[Abstract/Free Full Text]
  31. Denhardt, D. T. (1996) Biochem. J. 318, 729-747[Medline] [Order article via Infotrieve]
  32. Dent, P., Haser, W., Haystead, T. A. J., Vincent, L. A., Roberts, T. M., and Sturgill, T. W. (1992) Science 257, 1404-1407[Medline] [Order article via Infotrieve]
  33. Howe, L. R., Leevers, S. J., Gomez, N., Nakielny, S., Cohen, P., and Marshall, C. J. (1992) Cell 71, 335-342[Medline] [Order article via Infotrieve]
  34. Kyriakis, J. M., App, H., Zhang, X., Banerjee, P., Brautigan, D. L., Rapp, U. R., and Avruch, J. (1992) Nature 358, 417-421[CrossRef][Medline] [Order article via Infotrieve]
  35. Daum, G., Eisenmann-Tappe, I., Fries, H.-W., Troppmair, J., and Rapp, U. R. (1994) Trends Biochem. Sci. 19, 474-480[CrossRef][Medline] [Order article via Infotrieve]
  36. Downward, J. (1994) FEBS Lett. 338, 113-117[CrossRef][Medline] [Order article via Infotrieve]
  37. Pawson, T. (1995) Nature 373, 477-478[CrossRef][Medline] [Order article via Infotrieve]
  38. Pawson, T. (1995) Nature 373, 573-580[CrossRef][Medline] [Order article via Infotrieve]
  39. Troppmair, J., Bruder, J. T., App, H., Cai, H., Liptak, L., Szeberenyi, J., Cooper, G. M., and Rapp, U. R. (1992) Oncogene 7, 1867-1873[Medline] [Order article via Infotrieve]
  40. Dent, P., and Sturgill, T. W. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 9544-9548[Abstract/Free Full Text]
  41. Leevers, S. J., Paterson, H. F., and Marshall, C. J. (1994) Nature 369, 411-414[CrossRef][Medline] [Order article via Infotrieve]
  42. Avruch, J., Zhang, X.-f., and Kyriakis, J. M. (1994) Trends Biochem. Sci. 19, 279-283[CrossRef][Medline] [Order article via Infotrieve]
  43. Marais, R., Light, Y., Paterson, H. F., and Marshall, C. J. (1995) EMBO J. 14, 3136-3145[Abstract]
  44. Marais, R., Light, Y., Paterson, H. F., Mason, C. S., and Marshall, C. J. (1997) J. Biol. Chem. 272, 4378-4383[Abstract/Free Full Text]
  45. Sadoshima, J., and Izumo, S. (1996) EMBO J. 15, 775-787[Abstract]
  46. Thorburn, A., Thorburn, J., Chen, S. Y., Powers, S., Shubeita, H. E., Feramisco, J. R., and Chien, K. R. (1993) J. Biol. Chem. 268, 2244-2249[Abstract/Free Full Text]
  47. Cooper, J. A., and Howell, B. (1993) Cell 73, 1051-1054[Medline] [Order article via Infotrieve]
  48. Kefalas, P., Brown, T. R., and Brickell, P. M. (1995) Int. J. Biochem. Cell Biol. 27, 551-563[CrossRef][Medline] [Order article via Infotrieve]
  49. Erpel, T., and Courtneidge, S. A. (1995) Curr. Opin. Cell Biol. 7, 176-182[CrossRef][Medline] [Order article via Infotrieve]
  50. Superti-Furga, G., and Courtneidge, S. A. (1995) BioEssays 17, 321-330[Medline] [Order article via Infotrieve]
  51. Sugden, P. H., and Clerk, A. (1997) Cell. Signalling 9, 337-351[CrossRef][Medline] [Order article via Infotrieve]
  52. Cherrington, J. M., and Mocarski, E. S. (1989) J. Virol. 63, 1435-1440[Medline] [Order article via Infotrieve]
  53. Abdellatif, M., MacLellan, W. R., and Schneider, M. D. (1994) J. Biol. Chem. 269, 15423-15426[Abstract/Free Full Text]
  54. Brand, T., MacLellan, W. R., and Schneider, M. D. (1993) J. Biol. Chem. 268, 11500-11503[Abstract/Free Full Text]
  55. MacLellan, W. R., Lee, T.-C., Schwartz, R. J., and Schneider, M. D. (1994) J. Biol. Chem. 269, 16754-16760[Abstract/Free Full Text]
  56. Parker, T. G., Chow, K.-L., Schwartz, R. J., and Schneider, M. D. (1992) J. Biol. Chem. 267, 3343-3350[Abstract/Free Full Text]
  57. Gillespie-Brown, J., Fuller, S. J., Bogoyevitch, M. A., Cowley, S., and Sugden, P. H. (1995) J. Biol. Chem. 270, 28092-28096[Abstract/Free Full Text]
  58. Fire, A., Harrison, S. W., and Dixon, D. (1990) Gene (Amst.) 93, 189-198[CrossRef][Medline] [Order article via Infotrieve]
  59. Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual, pp. 1.33-1.41, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
  60. Iwaki, K., Sukhatme, V. P., Shubeita, H. E., and Chien, K. R. (1990) J. Biol. Chem. 265, 13809-13817[Abstract/Free Full Text]
  61. Smith, M. R., DeGudicbus, S. J., and Stacey, D. W. (1986) Nature 320, 540-543[Medline] [Order article via Infotrieve]
  62. Kolch, W., Heidecker, G., Lloyd, P., and Rapp, U. R. (1991) Nature 349, 426-428[CrossRef][Medline] [Order article via Infotrieve]
  63. Thorburn, J., and Thorburn, A. (1994) Biochem. Biophys. Res. Commun. 202, 1586-1591[CrossRef][Medline] [Order article via Infotrieve]
  64. Sabe, H., Knudsen, B., Okada, M., Nada, S., Nakagawa, H., and Hanafusa, H. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 2190-2194[Abstract]
  65. Fuller, S. J., Davies, E. L., Gillespie-Brown, J., Sun, H., and Tonks, N. K. (1997) Biochem. J. 323, 313-319[Medline] [Order article via Infotrieve]
  66. Superti-Furga, G. (1995) FEBS Lett. 369, 62-66[CrossRef][Medline] [Order article via Infotrieve]
  67. Heidecker, G., Huleihel, M., Cleveland, J. L., Beck, P., Lloyd, P., Pawson, T., and Rapp, U. R. (1990) Mol. Cell. Biol. 10, 2503-2512[Medline] [Order article via Infotrieve]
  68. Williams, N. G., Roberts, T. M., and Li, P. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 2922-2926[Abstract]
  69. Fabian, J. R., Daar, I. O., and Morrison, D. K. (1993) Mol. Cell. Biol. 13, 7170-7179[Abstract]
  70. Thorburn, J., McMahon, M., and Thorburn, A. (1994) J. Biol. Chem. 269, 30580-30586[Abstract/Free Full Text]
  71. Marshall, M. S. (1995) FASEB J. 9, 1311-1318[Abstract/Free Full Text]
  72. Decock, J. B. J., Gillespie-Brown, J., Parker, P. J., Sugden, P. H., and Fuller, S. J. (1994) FEBS Lett. 356, 275-278[CrossRef][Medline] [Order article via Infotrieve]
  73. Bogoyevitch, M. A., Gillespie-Brown, J., Ketterman, A. J., Fuller, S. J., Ben-Levy, R., Ashworth, A., Marshall, C. J., and Sugden, P. H. (1996) Circ. Res. 79, 162-173[Abstract/Free Full Text]
  74. Ramirez, M. T., Sah, V. P., Zhao, X.-L., Hunter, J. J., Chien, K. R., and Brown, J. H. (1997) J. Biol. Chem. 272, 14057-14061[Abstract/Free Full Text]
  75. Abdellatif, M., and Schneider, M. D. (1997) J. Biol. Chem. 272, 525-533[Abstract/Free Full Text]
  76. Brott, B. K., Decker, S., Shafer, J., Gibbs, J. B., and Jove, R. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 755-759[Abstract]
  77. Tsukita, S., Oishi, K., Akiyama, T., Yamanashi, Y., and Yamamoto, T. (1991) J. Cell Biol. 113, 867-879[Abstract]
  78. Guan, J.-L., and Shalloway, D. (1992) Nature 358, 690-692[CrossRef][Medline] [Order article via Infotrieve]
  79. Schaller, M. D., Borgman, C. A., Cobb, B. S., Vines, R. R., Reynolds, A. B., and Parsons, J. T. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 5192-5196[Abstract]
  80. Glenney, J. R., and Zokas, L. (1989) J. Cell Biol. 108, 2401-2408[Abstract]
  81. Sakai, R., Iwamatsu, A., Hirano, N., Ogawa, S., Tanaka, T., Mano, H., Yazaki, Y., and Hirai, H. (1994) EMBO J. 13, 3748-3756[Abstract]
  82. Aikawa, R., Komuro, I., Yamazaki, T., Zou, Y. Z., Kudoh, S., Tanaka, M., Shiojima, I., Hiroi, Y., and Yazaki, Y. (1997) J. Clin. Invest. 100, 1813-1821[Abstract/Free Full Text]


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.